69 related articles for article (PubMed ID: 8610708)
1. Projecting disease when death is likely.
Hoover DR; Peng Y; Saah AJ; Detels RR; Rinaldo CR; Phair JP
Am J Epidemiol; 1996 May; 143(9):943-52. PubMed ID: 8610708
[TBL] [Abstract][Full Text] [Related]
2. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients.
Forthal DN; Landucci G; Haubrich R; Keenan B; Kuppermann BD; Tilles JG; Kaplan J
J Infect Dis; 1999 Oct; 180(4):1338-41. PubMed ID: 10479168
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
5. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Gallant JE; Moore RD; Richman DD; Keruly J; Chaisson RE
J Infect Dis; 1992 Dec; 166(6):1223-7. PubMed ID: 1358986
[TBL] [Abstract][Full Text] [Related]
6. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and T-lymphocyte subsets in 48 acquired immune deficiency syndrome patients with cytomegalovirus infections].
Jia CH; Wang L; Jing FH; Xie J; Qiu ZF; Li TS; Lyu W
Zhonghua Nei Ke Za Zhi; 2019 Mar; 58(3):191-197. PubMed ID: 30803177
[No Abstract] [Full Text] [Related]
8. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.
Sungkanuparph S; Chakriyanuyok T; Butthum B
J Infect; 2008 Jan; 56(1):40-3. PubMed ID: 18037166
[TBL] [Abstract][Full Text] [Related]
10. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
[TBL] [Abstract][Full Text] [Related]
12. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.
Lichtner M; Cicconi P; Vita S; Cozzi-Lepri A; Galli M; Lo Caputo S; Saracino A; De Luca A; Moioli M; Maggiolo F; Marchetti G; Vullo V; d'Arminio Monforte A;
J Infect Dis; 2015 Jan; 211(2):178-86. PubMed ID: 25081936
[TBL] [Abstract][Full Text] [Related]
14. Using multiple decrement models to estimate risk and morbidity from specific AIDS illnesses. Multicenter AIDS Cohort Study (MACS).
Hoover DR; Peng Y; Saah AJ; Detels RR; Day RS; Phair JP
Stat Med; 1996 Nov 15-30; 15(21-22):2307-21; discussion 2337-40. PubMed ID: 8931203
[TBL] [Abstract][Full Text] [Related]
15. Causes of death of HIV-infected persons in Ottawa, Ontario, 1984-1995.
Kravcik S; Hawley-Foss N; Victor G; Angel JB; Garber GE; Pagé S; Denommé N; O'Reilly L; Cameron DW
Arch Intern Med; 1997 Oct; 157(18):2069-73. PubMed ID: 9382662
[TBL] [Abstract][Full Text] [Related]
16. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
[TBL] [Abstract][Full Text] [Related]
17. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort.
Longini IM; Clark WS; Karon JM
Am J Epidemiol; 1993 Jun; 137(11):1229-40. PubMed ID: 8100682
[TBL] [Abstract][Full Text] [Related]
18. T-lymphocytopaenia, opportunistic infections and pathological findings in Ghanaian AIDS patients and their sexual partners.
Ayisi NK; Wiredu EK; Sata T; Nyadedzor C; Tsiagbe VK; Newman M; Cofie CN; Taneguchi K
East Afr Med J; 1997 Dec; 74(12):784-91. PubMed ID: 9557423
[TBL] [Abstract][Full Text] [Related]
19. Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.
Chakraborty A; Mahapatra T; Mahapatra S; Ansari S; Siddhanta S; Banerjee S; Banerjee D; Sarkar RN; Guha SK; Chakraborty N
PLoS One; 2015; 10(2):e0117466. PubMed ID: 25679798
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
